Dark

Check out our Level2View

SITC
SITE Centers Corp. Common Shares
stock NYSE

At Close

Apr 17, 2026 3:59:53 PM EDT

5.57USD+2.294%(+0.12)562,427

5.57Bid 5.58Ask 0.01Spread

Pre-market

0.00USD-100.000%(-5.45)0

After-hours

Apr 17, 2026 4:00:30 PM EDT

5.58USD+0.090%(+0.01)251

OverviewOptionsHistoricalExchangesShortsTrends

SITC Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

SITC Specific Mentions

As of Apr 18, 2026 1:00:50 AM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

26 days ago • u/wellherewearenot • r/biotech_stocks • replimune_fda_approval • C

The submission was based on a phase 2 trial of RP1 together with a PD-1 inhibitor in PD-1 inhibitor-resistant melanoma. The FDA took issue with the lack of control arm (therefore inability to determine the relative contribution of the two drugs to the response rate) and I believe there was also an issue with the lack of data proving that the subjects enrolled met the SITC consensus definition of PD-1 resistance.
I believe the second point is what is addressed in the resubmission.

sentiment -0.77

26 days ago • u/wellherewearenot • r/biotech_stocks • replimune_fda_approval • C

The submission was based on a phase 2 trial of RP1 together with a PD-1 inhibitor in PD-1 inhibitor-resistant melanoma. The FDA took issue with the lack of control arm (therefore inability to determine the relative contribution of the two drugs to the response rate) and I believe there was also an issue with the lack of data proving that the subjects enrolled met the SITC consensus definition of PD-1 resistance.
I believe the second point is what is addressed in the resubmission.

sentiment -0.77

Share